San Diego, CA, April 22, 2014 --(PR.com
)-- Epitope Diagnostics announced today the launch of two additions to their panel of fecal sample-based diagnostic kits: the qualitative and quantitative Helicobacter pylori antigen ELISA kits. These kits allow for the rapid detection of any active H. pylori infections within humans, as well as offering the ability to monitor the efficacy of treatment over time.
The qualitative EDI™ Fecal H. pylori Antigen ELISA Kit (KT-824) detects the presence of H. pylori antigen and displays results that can be interpreted by the naked eye, thus eliminating need for expensive plate reading equipment.
The quantitative EDI™ Fecal H. pylori Antigen ELISA Kit (KT-826) can reveal the exact concentration of H. pylori antigen, which may be an indication of the severity of infection. Both kits use liquid controls/standards with a ready-to-use tracer for convenience. Both assays can also be completed in less than 2 hours.
In addition, a novel fecal sample collection device was developed for use with these kits, allowing for a simple, clean collection process from which to run the assay. This device also fits within automated ELISA platforms, such as the Dynex DS2, DSX, etc.
“We’ve eliminated the need to dilute or reconstitute,” said Dr. Ping Gao, President & CEO of Epitope Diagnostics Inc. “This, along with the new sample collection device, has allowed our H. pylori ELISA kits to be incredibly user friendly.”
Helicobacter pylori is a bacterium that can cause gastritis and peptic ulcers, and has also been linked to occurrences of stomach cancer. It is transmissible and the most widespread infection in the world, with bacteria present in about half the population.
About Epitope Diagnostics, Inc.
Established since 2003, Epitope Diagnostics, Inc. is an ISO 13845 certified medical device manufacturing company located in the Sorrento Valley biotech hub of San Diego, California. They specialize in development and manufacture of immunoassays for the global medical device and diagnostics industry. Their areas of interest include gastrointestinal, cardiovascular, infectious and autoimmune disease, as well as tumors/cancers and calcium/bone metabolism.